Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC
Provided By GlobeNewswire
Last update: Jan 28, 2025
- PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)
- Commercial capabilities build out in process, with proposed launch in PSVT targeted for mid-2025
Read more at globenewswire.com
